AU2016252008B2 - Polypeptides targeting HIV fusion - Google Patents

Polypeptides targeting HIV fusion Download PDF

Info

Publication number
AU2016252008B2
AU2016252008B2 AU2016252008A AU2016252008A AU2016252008B2 AU 2016252008 B2 AU2016252008 B2 AU 2016252008B2 AU 2016252008 A AU2016252008 A AU 2016252008A AU 2016252008 A AU2016252008 A AU 2016252008A AU 2016252008 B2 AU2016252008 B2 AU 2016252008B2
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
adnectin
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016252008A
Other languages
English (en)
Other versions
AU2016252008A1 (en
Inventor
Jonathan Davis
Mark R. Krystal
David L. Wensel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of AU2016252008A1 publication Critical patent/AU2016252008A1/en
Assigned to VIIV Healthcare UK (No.5) Limited reassignment VIIV Healthcare UK (No.5) Limited Amend patent request/document other than specification (104) Assignors: VIIV HEALTHCARE UK (NO 5) LIMITED
Application granted granted Critical
Publication of AU2016252008B2 publication Critical patent/AU2016252008B2/en
Priority to AU2019226255A priority Critical patent/AU2019226255A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
AU2016252008A 2015-04-24 2016-04-14 Polypeptides targeting HIV fusion Ceased AU2016252008B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019226255A AU2019226255A1 (en) 2015-04-24 2019-09-06 Polypeptides targeting hiv fusion

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US62/152,271 2015-04-24
US201562257474P 2015-11-19 2015-11-19
US62/257,474 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019226255A Division AU2019226255A1 (en) 2015-04-24 2019-09-06 Polypeptides targeting hiv fusion

Publications (2)

Publication Number Publication Date
AU2016252008A1 AU2016252008A1 (en) 2017-11-09
AU2016252008B2 true AU2016252008B2 (en) 2019-06-13

Family

ID=55809237

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016252008A Ceased AU2016252008B2 (en) 2015-04-24 2016-04-14 Polypeptides targeting HIV fusion
AU2019226255A Abandoned AU2019226255A1 (en) 2015-04-24 2019-09-06 Polypeptides targeting hiv fusion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019226255A Abandoned AU2019226255A1 (en) 2015-04-24 2019-09-06 Polypeptides targeting hiv fusion

Country Status (25)

Country Link
US (2) US10407490B2 (https=)
EP (2) EP3985020A1 (https=)
JP (3) JP6894846B2 (https=)
KR (1) KR20170138558A (https=)
CN (1) CN107922474A (https=)
AU (2) AU2016252008B2 (https=)
BR (1) BR112017022790A2 (https=)
CA (1) CA2983276A1 (https=)
CL (1) CL2017002687A1 (https=)
CO (1) CO2017011583A2 (https=)
CR (1) CR20170482A (https=)
DO (1) DOP2017000246A (https=)
EA (1) EA035332B1 (https=)
ES (1) ES2884267T3 (https=)
HK (1) HK1243432A1 (https=)
IL (1) IL255122A0 (https=)
MA (2) MA56222A (https=)
MX (1) MX2017013687A (https=)
PE (1) PE20180162A1 (https=)
PH (1) PH12017501914A1 (https=)
PT (1) PT3286212T (https=)
SG (1) SG11201708441RA (https=)
TW (1) TW201643185A (https=)
UY (1) UY36650A (https=)
WO (1) WO2016171980A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
JP2021507717A (ja) * 2017-12-18 2021-02-25 ビーブ、ヘルスケア、ユーケー、（ナンバー５）、リミテッドＶｉｉｖ Ｈｅａｌｔｈｃａｒｅ Ｕｋ （Ｎｏ．５） Ｌｉｍｉｔｅｄ 抗原結合性ポリペプチド
CN108997482B (zh) * 2018-08-09 2025-09-09 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
DK1712623T3 (da) 1997-01-21 2012-02-06 Gen Hospital Corp Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
CA2416219C (en) 2000-07-11 2016-10-11 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1543166A4 (en) * 2002-09-27 2009-10-28 Genentech Inc SYNERGETIC COMPOSITIONS FOR PREVENTING AND TREATING THE ACQUIRED IMMUNE WEAKNESS SYNDROME
ES2655912T3 (es) 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
JP2011507543A (ja) 2007-12-27 2011-03-10 ノバルティス アーゲー 改善されたフィブロネクチンベースの結合分子およびそれらの使用
PL2274331T3 (pl) 2008-05-02 2014-04-30 Novartis Ag Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
BRPI0919881B1 (pt) * 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
EA022983B1 (ru) * 2010-04-13 2016-04-29 Бристол-Майерс Сквибб Компани Белки на основе структурного домена фибронектина, связывающие pcsk9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
JP2014504587A (ja) * 2010-12-22 2014-02-24 ブリストル−マイヤーズ スクイブ カンパニー Ｉｌ−２３に結合するフィブロネクチンをベースとするスカフォールドドメインタンパク質
AU2012260434A1 (en) * 2011-05-23 2013-10-31 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EP2761066B1 (en) * 2011-09-27 2018-12-05 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
EP2951206A2 (en) * 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition

Also Published As

Publication number Publication date
TW201643185A (zh) 2016-12-16
SG11201708441RA (en) 2017-11-29
BR112017022790A2 (pt) 2018-07-17
JP2021035951A (ja) 2021-03-04
HK1243432A1 (zh) 2018-07-13
KR20170138558A (ko) 2017-12-15
CN107922474A (zh) 2018-04-17
JP2023055875A (ja) 2023-04-18
JP6894846B2 (ja) 2021-06-30
UY36650A (es) 2016-11-30
JP7465378B2 (ja) 2024-04-10
EP3286212B1 (en) 2021-06-02
AU2019226255A1 (en) 2019-09-26
CL2017002687A1 (es) 2018-04-20
US20190359688A1 (en) 2019-11-28
EP3286212A1 (en) 2018-02-28
MA41943A (fr) 2018-02-28
MA56222A (fr) 2022-04-20
CO2017011583A2 (es) 2018-04-19
MX2017013687A (es) 2018-07-06
DOP2017000246A (es) 2018-01-31
US11155602B2 (en) 2021-10-26
JP2018516247A (ja) 2018-06-21
CA2983276A1 (en) 2016-10-27
US10407490B2 (en) 2019-09-10
EP3985020A1 (en) 2022-04-20
US20180111980A1 (en) 2018-04-26
EA035332B1 (ru) 2020-05-28
CR20170482A (es) 2018-03-07
PH12017501914A1 (en) 2018-03-05
IL255122A0 (en) 2017-12-31
AU2016252008A1 (en) 2017-11-09
ES2884267T3 (es) 2021-12-10
WO2016171980A1 (en) 2016-10-27
PE20180162A1 (es) 2018-01-18
PT3286212T (pt) 2021-08-24
EA201792269A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
US11155602B2 (en) Polypeptides targeting HIV fusion
DK2697257T3 (en) FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
CA2884730C (en) Fibronectin based scaffold domain proteins that bind to myostatin
DK2443137T3 (en) NOVEL chemokine-binding peptides capable of impeding the sequence for immunity, inflammation and cancer
TW201130501A (en) Fibronectin based scaffold domain proteins that bind IL-23
EP2576615A2 (en) Fibronectin based scaffold proteins having improved stability
Meng et al. Design and biological evaluation of m-xylene Thioether-stapled short helical peptides targeting the HIV-1 gp41 Hexameric coiled–coil fusion complex
US20240239877A1 (en) Antigen binding polypeptides
US20250129161A1 (en) HIV Specific Binding Molecules and Uses Thereof
US12103971B2 (en) HIV specific binding molecules
CN118510536A (zh) 松弛素-2融合蛋白类似物及其使用方法
Egerer et al. The Prevention of HIV Infection with Viral Entry Inhibitors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: VIIV HEALTHCARE UK (NO.5) LIMITED

Free format text: FORMER NAME(S): VIIV HEALTHCARE UK (NO 5) LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired